Receiving a diagnosis of breast cancer can feel overwhelming, and making treatment decisions is not always easy. The **DEFINITIVE study** was created to help make this journey clearer and more personalized for people with early-stage HER2-positive breast cancer.
This European research study, funded by the European Commission (Project Number 101136953), aims to show that using a personalized diagnostic test called HER2DX® can help doctors choose treatments that maintain excellent outcomes while improving quality of life. In other words, the goal is to ensure that patients receive the treatment they need—no more and no less—without compromising effectiveness or survival.
The study brings together **18 expert partners from 7 European countries**, including doctors, researchers, and patient-focused organizations, all working together to improve care for people affected by breast cancer.
HER2DX®, developed by REVEAL GENOMICS®, is an innovative diagnostic test designed to support more personalized treatment decisions for HER2-positive breast cancer.
The test looks at the activity of 27 genes related to how breast cancer develops and behaves. It combines this genetic information with clinical details doctors already use, such as:
-The size of the tumor
-Whether lymph nodes are affected
All of this information is analyzed using advanced artificial intelligence to provide results that help doctors better understand how the cancer may behave and how likely it is to respond to treatment.
HER2DX® has already been studied in **more than 2,000 patients**, showing promising results in helping guide treatment decisions.
Every patient is different, and breast cancer does not affect everyone in the sameway. The test is designed to bring greater clarity and confidence to treatment planning.
The DEFINITIVE study will help confirm how useful this test is in everyday clinical practice and whether it can improve patients’ experiences and well-being.
Potential benefits include:
1. More Personalized Treatment: HER2DX®helps doctors estimate the risk of cancer returning and how likely a patient isto benefit from certain treatments. This means:
Some patients may be able to receive less intensive treatment, with fewer side effects, while still achieving excellent results.
- Others who have a higher risk may receive more targeted and intensive care to offer the best possible protection.
2. Better Decisions Before Surgery
Some treatments are given before surgery to shrink the tumor. HER2DX® provides additional information that helps doctors predict whether the cancer is likely to fully respond to treatment. This can help choose the most effective therapy plan from the start.
3. Clearer Planning After Surgery
After surgery, HER2DX® may help determine whether further treatment is needed and for how long. This can help avoid unnecessary treatments for some patients, while ensuring others receive the support they need.
Taking part in a clinical study is a personal decision. Participation in the DEFINITIVE study is completely voluntary, and choosing not to take part will not affect your medical care in any way.
If you would like to learn more or explore whether this study might be right for you, we encourage you to:
* Speak with your oncologist, or
* Contactthe study team at info@reveal-genomics.com
